Affordable Access

Publisher Website

Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor.

  • Sidibe, Fatoumata1
  • Spanoudaki, Anastasia1, 2
  • Vanneaux, Valerie3, 4
  • Mbemba, Elisabeth1
  • Larghero, Jerome3, 4
  • Van Dreden, Patrick5
  • Lotz, Jean-Pierre6
  • Elalamy, Ismail1, 2
  • Larsen, Annette K1
  • Gerotziafas, Grigoris T1, 2
  • 1 1 INSERM U938, Institut Universitaire de Cancérologie, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France. , (France)
  • 2 2 Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris, Paris, France. , (France)
  • 3 3 INSERM UMR1160, Institut Universitaire d'Hématologie, Paris, France. , (France)
  • 4 4 Assistance Publique Hôpitaux de Paris, Hôpital Saint Louis, Unité de Thérapie Cellulaire et Centre d'Investigation Clinique en Biothérapies (CICBT), Univ Paris Diderot, Sorbonne Paris Cité, Paris, France. , (France)
  • 5 5 Research and Development, Diagnostica Stago, Gennevilliers, France. , (France)
  • 6 6 Service d'Oncologie Médicale et de Thérapie Cellulaire, Hôpitaux Universitaires de l'Est-Parisien, Institut Universitaire de Cancérologie, Université Pierre et Marie Curie APREC, Paris, France. , (France)
Published Article
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Publication Date
May 01, 2018
DOI: 10.1177/1076029617715116
PMID: 28681632


The beneficial effect of autologous peripheral blood stem cell transplantation (APBSCT) may be compromised by acute vascular complications related to hypercoagulability. We studied the impact of graft product on thrombin generation of normal plasma and the expression of tissue factor (TF) and procoagulant platelet-derived procoagulant microparticles (Pd-MPs) in samples of graft products. Graft products from 10 patients eligible for APBSCT were mixed with platelet-poor plasma (PPP) or platelet-rich plasma (PRP) from healthy volunteers and assessed for in vitro thrombin generation. In control experiments, thrombin generation was assessed in (1) PPP and PRP without any exogenous TF and/or procoagulant phospholipids, (2) PPP with the addition of TF (5 pM) and procoagulant phospholipids (4 μM), (3) in PRP with the addition of TF (5 pM). Graft products were assessed with Western blot assay for TF expression, with a specific clotting assay for TF activity and with flow cytometry assay for Pd-MPs. The graft product enhanced thrombin generation and its procoagulant activity was related to the presence of Pd-MPs and TF. The concentration of Pd-MPs in the graft product was characterized by a significant interindividual variability. The present study reveals the need for a thorough quality control of the graft products regarding their procoagulant potential.

Report this publication


Seen <100 times